MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation

Cancer Biology and Therapy

Volumn 13, Issue 5, 2012, Pages 281-288

  Wu, Hao ^a   Huang, Min ^a   Cao, Peng ^b   Wang, Tongshan ^a   Shu, Yongqian ^a   Liu, Ping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Province Institute of Traditional Chinese Medicine   (China)

Author keywords

Cyclin D1; Gastric cancer; JAK2; MiR 135a

Indexed keywords

CYCLIN D1; JANUS KINASE 2; MICRORNA; MICRORNA 135A; PROTEIN BCL XL; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER;

EID: 84863294794     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.18943     Document Type: Article

References (31)

1. Kato M, Slack FJ. MicroRNAs: small molecules with big roles - C. elegans to human cancer. Biol Cell 2008; 100:71-81; PMID:18199046; http://dx.doi. org/10.1042/BC20070078.
2. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet 2006; 15:17-29; PMID:16651366; http:// dx.doi.org/10.1093/hmg/ddl046.
3. Yoda M, Kawamata T, Paroo Z, Ye X, Iwasaki S, Liu Q, et al. ATP-dependent human RISC assembly pathways. Nat Struct Mol Biol 2010; 17:17-23; PMID:19966796; http://dx.doi.org/10.1038/nsmb.1733.
4. Ahmed FE. Role of miRNA in carcinogenesis and biomarker selection: a methodological view. Expert Rev Mol Diagn 2007; 7:569-603; PMID:17892365; http:// dx.doi.org/10.1586/14737159.7.5.569.
5. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development 2005; 132:4653-62; PMID:16224045; http://dx.doi. org/10.1242/dev.02073.
6. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011; 91:827-87; PMID:21742789; http://dx.doi.org/10.1152/phys-rev. 00006.2010.
7. Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol 2011; 223:102- 15; PMID:21125669; http://dx.doi.org/10.1002/ path.2806.
8. Patel SH, Kooby DA. Gastric adenocarcinoma surgery and adjuvant therapy. Surg Clin North Am 2011; 91:1039-77; PMID:21889029; http://dx.doi. org/10.1016/j.suc.2011.06.009.
9. Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J, et al. MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene 2010; 29:5761- 71; PMID:20802530; http://dx.doi.org/10.1038/ onc.2010.352.
10. Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg 2010; 14:1170-9; PMID:20422307; http://dx.doi.org/10.1007/ s11605-010-1202-2.
11. Gao CP, Zhang ZY, Cai GH, Liu WZ, Xiao SD, Lu H. Reduced expression of miR-218 and its significance in gastric cancer. Zhonghua Zhong Liu Za Zhi 2010; 32:249-52; PMID:20510072.
12. Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 2011; 17:2725-33; PMID:21220473; http://dx.doi.org/10.1158/1078-0432.CCR-10-2132.
13. Gao C, Zhang Z, Liu W, Xiao S, Gu W, Lu H. Reduced microRNA-218 expression is associated with high nuclear factor kappaB activation in gastric cancer. Cancer 2010; 116:41-9; PMID:19890957.
14. Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol 2008; 18:545-51; PMID:18848449; http://dx.doi.org/10.1016/j. tcb.2008.08.008.
15. Ingley E, Klinken SP. Cross-regulation of JAK and Src kinases. Growth Factors 2006; 24:89-95; PMID:16393697; http://dx.doi. org/10.1080/ 08977190500368031.
16. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007; 178:2623-9; PMID:17312100.
17. Yu LF, Zhu YB, Qiao MM, Zhong J, Tu SP, Wu YL. Constitutive activation and clinical significance of Stat3 in human gastric cancer tissues and cell lines. Zhonghua Yi Xue Za Zhi 2004; 84:2064-9; PMID:15730617.
18. Vera J, Rateitschak K, Lange F, Kossow C, Wolkenhauer O, Jaster R. Systems biology of JAK-STAT signalling in human malignancies. Prog Biophys Mol Biol 2011; 106:426-34; PMID:21762720; http://dx.doi. org/10.1016/j.pbiomolbio. 2011.06.013.
19. Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 2008; 33:122-31; PMID:18291658; http://dx.doi. org/10.1016/j.tibs.2007.12.002.
20. Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 2006; 71:713- 21; PMID:16426581; http://dx.doi.org/10.1016/j. bcp.2005.12.017.
21. Benes V, Castoldi M. Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 2010; 50:244- 9; PMID:20109550; http://dx.doi.org/10.1016/j. ymeth.2010.01.026.
22. Witkos TM, Koscianska E, Krzyzosiak WJ. Practical aspects of microRNA target prediction. Curr Mol Med 2011; 11:93-109; PMID:21342132; http://dx.doi. org/10.2174/156652411794859250.
23. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009; 374:477-90; PMID:19625077; http://dx.doi.org/10.1016/S0140- 6736(09)60617-6.
24. Rathbone M, Rathbone B. Helicobacter pylori and Gastric Cancer. Recent Results Cancer Res 2011; 185:83-97; PMID:21822821; http://dx.doi. org/10.1007/978-3-642-03503-6-5.
25. Bornschein J, Malfertheiner P. Gastric carcinogenesis. Langenbecks Arch Surg 2011; 396:729-42; PMID:21611816; http://dx.doi.org/10.1007/s00423- 011-0810-y.
26. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010; 11:136-46; PMID:20022810; http://dx.doi. org/10.1016/S1470-2045(09)70343-2.
27. Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B, et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 2009; 114:2945-51; PMID:19666866; http://dx.doi. org/10.1182/blood-2009-02-204842.
28. Liu S, Guo W, Shi J, Li N, Yu X, Xue J, et al. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol 2011; In press; PMID:21888875; http://dx.doi.org/10.1016/j. jhep.2011.08.008.
29. Smirnova OV, Ostroukhova TY, Bogorad RL. JAKSTAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression? World J Gastroenterol 2007; 13:6478-91; PMID:18161917; http://dx.doi. org/10.3748/wjg.13.6478.
30. Santos FP, Verstovsek S. JAK2 inhibitors: what's the true therapeutic potential? Blood Rev 2011; 25:53- 63; PMID:21095048; http://dx.doi.org/10.1016/ j. blre.2010.10.004.
31. Quintás-Cardama A, Verstovsek S. New JAK2 inhibitors for myeloproliferative neoplasms. Expert Opin Investig Drugs 2011; 20:961-72; PMID:21521147; http://dx.doi.org/10.1517/13543784.2011.579560.